The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold

Anthony L Gotter1, Christopher J Winrow1, Joseph Brunner1, Susan L Garson1, Steven V Fox2, Jacquelyn Binns2, Charles M Harrell1, Donghui Cui3, Ka Lai Yee3, Mark Stiteler2, Joanne Stevens2, Alan Savitz2, Pamela L Tannenbaum2, Spencer J Tye2, Terrence McDonald1, Leon Yao2, Scott D Kuduk4, Jason Uslaner2, Paul J Coleman4 and John J Renger1*

Abstract

Background: Drugs targeting insomnia ideally promote sleep throughout the night, maintain normal sleep architecture, and are devoid of residual effects associated with morning sedation. These features of an ideal compound are not only dependent upon pharmacokinetics, receptor binding kinetics, potency and pharmacodynamic activity, but also upon a compound’s mechanism of action.

Results: Dual orexin receptor antagonists (DORAs) block the arousal-promoting activity of orexin peptides and, as demonstrated in the current work, exhibit an efficacy signal window dependent upon oscillating levels of endogenous orexin neuropeptide. Sleep efficacy of structurally diverse DORAs in rat and dog was achieved at plasma exposures corresponding to orexin 2 receptor (OX2R) occupancies in the range of 65 to 80%. In rats, the time course of OX2R occupancy was dependent upon receptor binding kinetics and was tightly correlated with the timing of active wake reduction. In rhesus monkeys, direct comparison of DORA-22 with GABA-A modulators at similar sleep-inducing doses revealed that diazepam produced next-day residual sleep and both diazepam and eszopiclone induced next-day cognitive deficits. In stark contrast, DORA-22 did not produce residual effects. Furthermore, DORA-22 evoked only minimal changes in quantitative electroencephalogram (qEEG) activity during the normal resting phase in contrast to GABA-A modulators which induced substantial qEEG changes.

Conclusion: The higher levels of receptor occupancy necessary for DORA efficacy require a plasma concentration profile sufficient to maintain sleep for the duration of the resting period. DORAs, with a half-life exceeding 8 h in humans, are expected to fulfill this requirement as exposures drop to sub-threshold receptor occupancy levels prior to the wake period, potentially avoiding next-day residual effects at therapeutic doses.

Keywords: Dual orexin receptor antagonist, Suvorexant, Receptor occupancy, Residual effects

Background

As a primary arousal signal in wake control, orexin signaling is necessary for normal circadian regulation of consolidated wakefulness; exogenous application of orexin neuropeptides or optogenetic activation of orexin neurons induce arousal and genetic loss of orexin signaling is associated with narcoleptic symptoms [1,2]. Endogenous orexin peptide levels oscillate over the course of the day: secretion during waking hours induces a peak in orexin levels late in the active phase, and rapidly decreasing activity precedes a nadir in levels during the inactive phase [3,4]. Orexin-A (OX-A) and -B (OX-B) are processed peptide products of the HCRT (hypocretin) gene, which encodes the prepro-orexin peptide [5]. OX-A has similar affinity for both orexin-1 and -2 receptors (OX1R and OX2R, respectively), while OX-B selectively favors OX2R binding [6]. Exogenous administration of OX-A is most effective in promoting wakefulness when applied during
inactive-phase periods when the endogenous levels are normally low [7-9]. Conversely, blocking orexin activity with dual orexin receptor antagonists (DORAs) is most easily measured during the active phase [10-12].

Therapy targeting insomnia requires defined pharmacodynamic timing. Unlike most other central nervous system therapeutics, compounds utilized in the therapeutic treatment of insomnia will, ideally, promote sleep throughout the resting period, maintain normal sleep architecture, and avoid residual effects upon waking, thus allowing for full wakefulness during the subsequent active period. This time-limited efficacy requires pharmacokinetic exposure and sufficient central receptor occupancy levels to drive sleep efficacy when desired, and reduced compound exposure to avoid residual effects upon waking. This limitation of duration of activity makes the half-life ($T_{1/2}$) of γ-aminobutyric acid (GABA-A) receptor modulators a key defining feature of their clinical utility. Next-day/carry-over effects, in particular, are well-documented undesirable mechanism-related adverse effects of conventional therapies with long half-lives [13,14]. The current standards of care, benzodiazepine and non-benzodiazepine GABA-A receptor modulators, can also be associated with bothersome morning sedation and cognitive residual effects. In contrast, the current data on DORAs suggest that these compounds induce physiological sleep and demonstrate only mild residual effects despite relatively long plasma $T_{1/2}$ [10,12,15-18]. Preclinical studies of compounds with balanced potency at OX₁R and OX₂R, such as DORA-22, an analog of MK-6096 [2,18,19], demonstrate little or no effect on electroencephalogram (EEG) spectral frequency distribution, suggesting that blockade of orexin-mediated wakefulness allows sleep to occur that is similar to that measured in vehicle-treated controls [20].

Pharmacologically, the duration of sleep-promoting efficacy depends not only upon a compound’s mechanism of action, but also upon its pharmacokinetics, receptor-binding kinetics and potency, as these properties dictate the timing of receptor occupancy required for in vivo effects important for a compound’s overall activity and clinical utility. Clearly, rapid central nervous system penetration is essential for sleep-onset efficacy, and a moderate pharmacokinetic $T_{1/2}$ and sufficiently high receptor occupancies are required for sleep maintenance throughout the desired resting period. However, to avoid next-day residual effects, compound levels must drop below exposures required for minimum effective receptor occupancy by the onset of wakefulness to avoid residual sleep effects. In principle, compounds that are effective at a low receptor occupancies are challenged to restrict sleep promoting effects to the resting phase, compared to mechanisms that require a higher occupancy threshold that are less likely to exhibit carry-over effects for a given pharmacokinetic profile and $T_{1/2}$. Here, we characterize the pharmacokinetic and receptor occupancy properties underlying the timing of efficacy elicited by structurally distinct DORAs including DORA-12 and DORA-22, close analogs of suvorexant and MK-6096 whose chemical properties have been described previously [19,21,22]. The ensemble of pharmacokinetic, receptor-binding kinetics and pharmacodynamic properties of DORAs appear advantageous to restricting the wake-inhibition efficacy of these compounds to the resting phase.

**Results**

**OX-A levels are associated with wakefulness across species**

To more precisely define the timing of changes in orexin levels, their relationship with arousal and therefore the available signal window for the DORAs over the course of the circadian day, OX-A levels in cerebrospinal fluid (CSF) were determined by meso-scale immunoassay and correlated with baseline active wake as measured by polysomnography (PSG) in nocturnal and diurnal preclinical species. In nocturnal mice and rats, OX-A levels progressively drop during the inactive period, reaching a nadir in the second half of this period, and accumulate over the course of the dark (active) period (Figure 1A). Mean time in active wake generally mimics these OX-A levels. In diurnal dogs and rhesus monkeys, OX-A levels build during the light (active) period and fall during the resting period, coincident with increased arousal during the day and decreased wakefulness at night (Figure 1B). These observations predict that DORAs will have maximum efficacy in the late dark phase of nocturnal species and the late light phase of diurnal animals which correlates to the active periods of both types of species.

**DORA efficacy in rats is most salient during the active phase**

The sleep-promoting effects of DORAs were greatest during the active phase when orexin levels were highest in normal rats entrained to a 12:12 light:dark cycle. When administered during the mid-active phase, DORA-22 (30 mg/kg), an MK-6096 analog structurally distinct from suvorexant and DORA-12, promoted sleep characteristic of a DORA: active wake was attenuated for up to 8 h, and both delta and REM sleep were increased for up to 6 h following treatment (Figure 2A). The magnitude of wake-reducing activity was diminished when normal rats were administered DORA-12 just prior to the inactive phase onset and was accompanied by small variable increases in delta and rapid eye movement (REM) sleep (Figure 2B). Importantly, changes induced by DORA-22 administered just prior to the inactive phase trend in the same direction as that seen in vehicle-treated animals progressing from the active
to the inactive phase; namely, diminished active wake, increased slow wave sleep (SWS), and small fluctuations in REM sleep.

DORA-induced efficacy occurs at OX2R occupancies exceeding 65%

A dose response for DORA-12, a structural analog of suvorexant, was evaluated in rat PSG studies to determine the relationship between sleep-promoting efficacy as measured by active wake reduction and OX2R occupancy. Dose-dependent attenuation of active wake was observed with DORA-12 (Figure 3A), which also resulted in corresponding increases in non-REM and REM sleep. Sleep-promoting efficacy induced by each dose of DORA-12 was quantified as a percent change in active wake relative to the vehicle-induced response over 2 h following treatment.

Separately, the relationship between OX2R occupancy relative to plasma exposure was determined by administering DORA-12 intravenously (i.v.) over a range of doses to transgenic rats expressing human OX2R to determine a full occupancy curve over a wide range of plasma concentrations in order to define the maximal occupancy against which raw occupancy values could be normalized. This relationship was then used to determine the OX2R occupancy in PSG experiments from measured plasma concentrations. The maximum plasma concentration (Cmax) observed in satellite animals dosed in parallel with those used in PSG experiments were used for these analyses since Cmax occurs during the first two hours after treatment. Increased OX2R occupancy, achieved at higher doses, was accompanied by progressively greater attenuation of active wake (Figure 3B). This same pattern was also observed for suvorexant and

---

Figure 1 Active wake closely follows oscillating OX-A levels across preclinical species. The time course of OX-A levels in CSF and active wake were highest during the dark phase in nocturnal rodents (A) and during the light phase in diurnal species (B). Mean OX-A levels and time spent in active wake are plotted ± standard error of the mean (SEM) over a 24-h period (dark period shaded) for 6-h and 30-min intervals, respectively. OX-A levels were determined by meso-scale immunoassay at 6-h time points in mice (n = 3; 50 pooled CSF samples each), rats (n = 8 samples each), dogs (n = 8 samples each), and rhesus monkeys (n = 8 samples for ported animals, each). Mean time in active wake under baseline conditions was determined by EEG from telemeterized mice (6 days, n = 7), rats (6 days, n = 7), dogs (10 days, n = 6), and rhesus monkeys (5 days, n = 7).
structurally distinct compounds such as MK-6096 and DORA-22. Generally, compound-induced attenuation of active wake became salient and significant at OX2R occupancies between 63 and 83%. While 0.3 and 1 mg/kg doses of DORA-12 marginally reduced active wake, this change became highly significant at 3 mg/kg, where plasma levels reached 0.20 μM, corresponding to 83% OX2R occupancy (Figure 3, Table 1). For comparison, efficacy as determined by active wake reduction, plasma exposure, and OX2R occupancy in rats are presented for each dose of suvorexant and DORA-12 in Table 1.

It was previously shown that suvorexant attenuated active wake in dogs in a dose-dependent manner with corresponding increases in non-REM and REM sleep: the effects of 1 mg/kg on active wake were observed for up to 4 h, and 3 mg/kg responses for up to 7.5 h [12]. Re-examination of the time course of plasma exposures indicated that suvorexant efficacy was observed at time points when plasma concentrations were in excess of 0.342 μM (Figure 4A), a plasma exposure corresponding to 65.7% OX2R occupancy calculated from rat occupancy values normalized for both rat and dog unbound plasma values (1.4 and 1.0%, respectively). Time points showing active wake reduction following administration of suvorexant (1 and 3 mg/kg) coincided with plasma exposures that were calculated to result in ≥65% OX2R occupancy (Figure 4B), consistent with the range of effective occupancy observed in rats.

**OX2R binding kinetics contribute to the timing of DORA receptor occupancy**

To determine the influence of OX2R binding kinetics on receptor occupancy and sleep-promoting efficacy, the time course of *in vivo* effects in response to DORA-12 was compared with that of almorexant, a compound known to exhibit exceedingly slow dissociation from OX2R. Almorexant is well documented to have slow binding kinetics relative to other DORAs [18,23]. Depending upon the method and competing ligand used, the T_{1/2} of almorexant for association with OX2R ranges from 28 to 162 min and from 70 to 268 min for dissociation (the later values obtained in current experiments comparing 6 different DORAs in Table 2). DORA-12 (30 mg/kg) and almorexant
(100 mg/kg) were administered both during the mid-active phase and just prior to the inactive phase, a therapeutically relevant dosing time, in rats. DORA-12 significantly attenuated active wake for approximately 6 h following dosing during the active phase and up to 3.5 h after treatment at the inactive phase onset (P <0.05 through 0.001; see Figure 5A, upper panels). Almorexant-dependent reductions in active wake were seen for up to 7.5 h after treatment during the active phase and for up to 11 h following inactive-phase treatment (Figure 5B, upper panels).

Plasma and CSF levels of DORA-12 and almorexant, as well as OX2R occupancy were determined in satellite rats following treatment at the onset of the inactive phase. As seen in Figure 5A (lower panels), DORA-12 plasma and CSF levels began to fall immediately after dosing, with corresponding decreases in OX2R occupancy to 77% of maximum at 8 h, coincident with the cessation of sleep-promoting effects. OX2R occupancy by almorexant, however, remained elevated at 10 h, even though levels within the CSF were undetectable at this time point (Figure 5B, lower panels). The persistence of OX2R occupancy by almorexant despite disappearing levels of the compound in the plasma and CSF is consistent with its extremely slow receptor-binding kinetics relative to other DORAs including suvorexant, MK-6096, DORA-22 and SB-649868 (Table 2). Together these results indicate that binding kinetics have the capacity to influence receptor occupancy and sleep promoting efficacy, particularly for compounds with excessively slow kinetic parameters.

Next-day sleep, qEEG, and quantitative effects in rhesus monkeys

To evaluate the potential for both GABA-A receptor modulators and DORA-22 to promote sleep through the resting phase and into the subsequent active phase, rhesus monkeys were administered these compounds 2 h before lights out. The doses, diazepam at 10 mg/kg, eszopiclone at 10 mg/kg, and DORA-22 at 30 mg/kg, were selected based on their similar potential to promote sleep following active-phase dosing. Quantified over 2 h, these treatments have previously been found to attenuate active wake by 38.4, 55.0, and 40.1 min relative to vehicle, respectively [24].

Diazepam, eszopiclone, and DORA-22 produced characteristic plasma-exposure profiles (Figure 6A). The anxiolytic diazepam exhibited a peak at 1.0 h (775 nM), eszopiclone induced a more rapid $C_{\text{max}}$ at 0.5 h (1680 nM), and DORA-22 a more delayed exposure profile (134 nM at 2 h). All three compounds significantly attenuated active wake in the 2 h after dosing before the onset of the inactive phase (Figure 6B). Unlike eszopiclone and DORA-22, diazepam significantly atten-
ated active wake at time points 7.5 h into the inactive phase and 3 h into the subsequent active phase. Despite the presence of measurable eszopiclone and DORA-22 plasma levels 17 h after treatment, no consistent attenuation of active wake was observed in response to either compound the morning after treatment.

Quantitative EEG analysis performed coincident with PSG revealed time-dependent and qualitative differences between the effects of these compounds that were not evident in measurements of active wake. All three compounds increased delta frequency qEEG power in advance of the normal increase in delta power observed during the resting phase after administration of vehicle (Figure 6C, bottom panels). However, both diazepam and eszopiclone increased high-frequency gamma power and substantially decreased theta power throughout the inactive period, while DORA-22 had essentially no effect on these measures (Figure 6C, top and middle panels). The effects of diazepam persisted into the subsequent active period while eszopiclone-induced qEEG changes ceased abruptly upon lights on (at which point cognitive tests were performed). The relevance of compound-induced qEEG changes occurring during cognitive testing intervals is currently unknown.

In order to better understand the consequences of compound-induced sleep and qEEG effects that persist though the inactive period, cognitive memory and attention parameters were evaluated in the same rhesus monkeys, the morning after treatment. Memory was evaluated in the delayed match to sample (DMS) task performed at lights on (14 h after dosing), while attention was evaluated in the serial choice retention time (SCRT) test administered 2 h later (16 h after dosing; see Figure 6C, bottom panels, D and C time points). Significant deficits in recognition memory, as assessed by DMS, were observed the morning after treatment with diazepam (10 mg/kg) but not following eszopiclone (10 mg/kg) or DORA-22 (30 mg/kg) relative to their respective vehicle treatments (Figure 6D). These results are consistent with diazepam-dependent active wake attenuation persisting into the active period. Despite the presence of measurable levels of this DORA-22 three hours after the DMS task was performed (Figure 6A; 61 nM), no attenuation of in performance was observed. In SCRT, both diazepam and eszopiclone elicited significant

### Table 1 Efficacy as measured by active wake reduction by suvorexant and DORA-12 relative to plasma exposure and OX2R exposure in rats

| Compound | Dose (mg/kg) | Plasma (nM) | OX2R Occ (%) | Active wake reduction (%) |
|----------|-------------|-------------|--------------|--------------------------|
| Suvorexant | 10          | 1600.0      | 92.6         | -29.0***                |
|          | 30          | 2100.0      | 94.3         | -79.6**                 |
|          | 100         | 5100.0      | 97.6         | -79.9**                 |
| DORA-12  | 0.3         | 20.2        | 34.0         | -7.9                    |
|          | 1           | 67.4        | 62.8         | -9.7                    |
|          | 3           | 202.2       | 83.0         | -28.8***                |
|          | 10          | 674.0       | 93.9         | -44.2***                |
|          | 30          | 2022.0      | 97.1         | -45.9***                |

*Occ, occupancy.

*Normalized occupancy was determined over a range of doses and fit to a one-sided binding hyperbolic curve to determine the maximum occupancy. OX2R occupancies corresponding to plasma values at indicated doses were calculated based on the normalized curve for each compound.

*Mean percent change in active wake relative to vehicle in the 2 h following treatment (**, ***, p < 0.01, 0.001, population t-test).
Table 2 Orexin 2 receptor binding kinetic parameters for DORAs

| Compound  | $K_d$ (nM) | $T_{1/2}$ ON (min) | $K_{ON}$ (mol$^{-1} \cdot$ min$^{-1}$) | $T_{1/2}$ OFF (min) | $K_{OFF}$ (min$^{-1}$) |
|-----------|------------|-------------------|---------------------------------|-------------------|-----------------------|
| Almorexant| 0.048      | 162               | $1.58 \times 10^7$              | 268               | $2.696 \times 10^{-3}$ |
| Suvorexant| 0.401      | 80.1              | $7.63 \times 10^6$              | 89.4              | $7.784 \times 10^{-3}$ |
| DORA-12   | 0.157      | 57.5              | $2.77 \times 10^7$              | 232               | $3.154 \times 10^{-3}$ |
| MK-6096   | 0.338      | 62.9              | $1.69 \times 10^7$              | 118               | $6.754 \times 10^{-3}$ |
| DORA-22   | 0.834      | 24.7              | $9.19 \times 10^6$              | 37.8              | $1.878 \times 10^{-2}$ |
| SB-649868 | 0.163      | 37.0              | $2.56 \times 10^7$              | 57.0              | $1.258 \times 10^{-2}$ |

*Almorexant $T_{1/2}$ ON represents an underestimate as almorexant was applied at concentrations 3-fold above its $K_d$ in order to measure its kinetics alongside other DORAs.

$K_d$, binding constant; $K_{OFF}$, dissociation constant; $K_{ON}$, association constant; $T_{1/2}$ OFF, half-life off-rates; $T_{1/2}$ ON, binding half-life.

Figure 5 Time course of DORA-12 and almorexant OX2R occupancy and efficacy in rats. A (upper panels). The time course of DORA-12 (30 mg/kg) effects on active wake was determined in rats by telemetry PSG relative to vehicle (20% Vitamin E TPGS, p.o.) following treatment in active (n = 14) or inactive phase (n = 7). Time points at which significant differences exist between vehicle and DORA-12 responses are indicated by gray vertical lines and tick marks (short, medium, long marks: P < 0.05, 0.01, 0.001, respectively). B (upper panels). Effects of almorexant (100 mg/kg) on active wake relative to vehicle following treatment in active (n = 14) or inactive phase (n = 14). Lower panels. Plasma and CSF levels as well as OX2R receptor occupancy of DORA-12 (A) and almorexant (B) following inactive phase treatment (one male, one female animal per time point). Plasma, CSF, and occupancy levels were determined in the same animals, in satellite to PSG experiments.
deficits in the percentage of correct responses to cues of the shortest duration relative to vehicle-treated controls (P < 0.05 for both) (Figure 6E). In contrast, deficits in next-day attention were not observed with DORA-22.

Suvorexant exposure time course in humans
Plasma samples obtained in an Phase 1 clinical evaluation of suvorexant exhibited a common exposure profile, with a time to maximum plasma concentration...
(T\textsubscript{max}) of 3 h or less (Figure 7). Human free plasma levels of suvorexant sufficient for 65% OX\textsubscript{2}R occupancy were calculated based on extensive transgenic rat occupancy data and normalized for free fraction (rat: 1.4%; human: 1.0%). The human plasma concentration of suvorexant calculated to correspond to 65% OX\textsubscript{2}R occupancy is 0.33 μM (free + bound). Observed clinical suvorexant mean plasma concentrations fell below the levels predicted to correspond to 65% OX\textsubscript{2}R occupancy, where sleep-promoting efficacy is predicted, by the 8 h post-dose time point for both the 10 and 20 mg therapeutic doses. Together this analysis indicates that the sleep promoting effects of suvorexant would not be expected to persist into subsequent waking hours at therapeutic doses less than 20 mg.

**Discussion**

Timing of the pharmacodynamic efficacy of drugs targeting insomnia is critical to promote sleep maintenance throughout the resting phase and to avoid undesired next-day effects such as residual drowsiness upon waking. GABA-A receptor modulators, the current standard of care for insomnia, act by potentiating the activity of endogenous neurotransmitters and have a low standard of care for insomnia, act by potentiating the ac-

The etiology of insomnia is not well understood at the neurotransmitter or neuronal pathway level, and changes in orexin levels have yet to be demonstrated as a cause of insomnia. As such, translatable preclinical models for insomnia have not been developed and the studies performed in the current work only mimic the normal,
or healthy condition where orexin levels are diminished during the normal inactive phase. However, orexin levels have been observed to increase with wake-related motor activity associated with forced swimming in rats [26], in patients with restless legs syndrome [27], and are diminished in narcoleptic patients based on examination of CSF levels derived from lumbar collection [28]. Persistent and significant reductions in wakefulness have been observed during the resting phase of insomnia patients in response to suvorexant treatment [29] and to SB-649868 in a situational model of insomnia [15]. These clinical observations suggest that DORAs are effective in reversing elevated orexin signaling present in insomnia patients.

This work in rats and dogs demonstrates that salient sleep promotion by DORAs is achieved at plasma levels necessary for OX2R occupancy to exceed a threshold of 65 to 80% as calculated based on the transgenic rat model. Sleep promotion in dogs was observed at times during which suvorexant levels were sufficient for OX2R occupancies in excess of 65%. In rats, highly significant active wake attenuation in the 2 h following dosing of DORA-12 occurred at plasma concentrations corresponding to occupancies of 83% in transgenic animals, while a trend toward active wake reduction (~9.7%) was seen at an occupancy of 63% occupancies did not reach significance in this experiment. While it remains possible that variation in expression in transgenic animals expressing the human receptor may have contribute to slightly different levels of receptor occupancy, the similar in vitro potency of DORA-12 in humans and rats (FLIPR Kᵦ = 19 nM and 25 nM, respectively; unpublished observations) indicates that the results in transgenic animals were a reasonable facsimile of receptor binding in genetically unmodified animals. The 65 to 80% occupancy range is consistent with prior studies measuring OX2R occupancy by orexin antagonists in specific brain regions. Although efficacy thresholds were not explicitly defined, Dugovic et al. (2009) did not observe almorexant efficacy at 78% occupancy, and appeared to see significant changes at occupancies above 89% [29], while Morairty et al. (2012) saw differential sleep drop-off when OX2R occupancies diminished from 75 to 63% [30]. Moreover, effective occupancy thresholds of 65 to 90% for antagonists targeting CNS G protein coupled receptors such as neuroleptics for D2-like receptors, have been found previously [31,32]. Comparisons between methods, however, should be made with caution since different approaches utilizing varying assay incubation times coupled with differing compound off-rates can influence raw occupancy measurements. Importantly, the pattern of increased OX2R occupancy in rats alongside dose-dependent attenuation of active wake with structurally distinct DORAs observed herein and in other published studies [10,12,18] indicates that the occupancy threshold required for efficacy is a general property of orexin antagonism and is not compound dependent. These findings illustrate the importance of mechanism-dependent differences in receptor occupancy thresholds in determining the timing of sleep-promoting efficacy of GABA-A receptor modulators relative to DORAs. Ideally, insomnia treatments are expected to normalize the elevated levels of active wake experienced during disrupted sleep that are characteristic of insomnia during the resting period (Figure 8A). GABA-A receptor modulators, including diazepam (a benzodiazepine receptor modulator, BzRM) as well as zolpidem and eszopiclone (non-BzRMs), exhibit in vivo efficacy at a mean GABA-A receptor occupancy of 27%. Low levels of receptor engagement are likely due to the receptor activation mechanism of these compounds leading to amplification of cellular signaling [25]. This low threshold for efficacy presents a challenge to GABA-A receptor modulators to restrict their sleep-promoting effects to the inactive phase. GABA-A receptor occupancy by diazepam, an anxiolytic BzRM with a long T₁/₂, exceeds this occupancy threshold long into the subsequent active period at sleep-promoting doses. As a consequence, diazepam exhibits substantial residual effects (Figure 8B) in terms of both sedation and cognitive measures (see Figure 6). Non-BzRMs that have a shorter exposure T₁/₂ more rapidly exceed receptor occupancy thresholds sufficient for sleep promotion. However, depending on dosage, these non-BzRMs may not maintain sleep throughout the inactive period, resulting in early morning awakenings (Figure 8C). Identifying appropriate dosages that avoid residual effects but maintain resting-phase efficacy is complicated by the additional non-sleep-related effects of these compounds. In the current studies, eszopiclone-induced reductions in active wake were detectable for up to 6 h while qEEG effects were observed almost 14 h later and effects on attention for up to 16 h (see Figure 6).

In contrast, DORAs exhibit in vivo sleep effects at plasma exposures sufficient for 65% OX2R occupancy, the higher level of receptor engagement being required to sufficiently block the activating effect of the orexin ligand (Figure 8D). This high occupancy threshold requires DORAs to maintain plasma concentrations sufficient to promote sleep maintenance throughout the normal resting period. At the same time, DORAs are less likely to exhibit next-day residual somnolence despite being present at measurable plasma levels due to the high receptor occupancy threshold required for sleep maintenance. The sleep-promoting effects of falling levels of the antagonist at the onset of the normal waking phase are also likely to be countered by accumulating levels of the endogenous orexin ligand, which might provide an even faster cessation of DORA-induced
somnolence due to the competitive nature of the antagonists and the relatively close $K_i$ values.

Unlike GABA-A receptor modulators, DORA-22 did not exhibit next-day residual effects in rhesus monkeys despite the presence of measurable plasma levels 17 h after dosing. DORA-22 did not impact next-day sleep, qEEG, or cognitive measures as compound levels were insufficient to occupy OX$_2$R above the necessary efficacy threshold. Diazepam, an anxiolytic with a long $T_{1/2}$, promoted sleep throughout the normal resting period and into the subsequent active phase and also impacted memory and attention. Eszopiclone did not demonstrate next-day sleep effects or memory impairment; however, it did significantly impair attention as measured by SCRT. Although sleep effects did not persist with eszopiclone, qEEG spectral power changes were evident up to lights on/performance of DMS tasks. The effect of cognitive testing on qEEG measures is currently uncharacterized, and the effect of administering a treatment for insomnia in addition to cognitive testing on qEEG spectral power is even less certain. Direct compound effects may be one possible explanation for the next-day attention deficits found with eszopiclone, as measurable concentrations (535 nM) were reported 17 h after administration. Another possibility is that this attention deficit is a consequence of abnormal sleep occurring during the previous inactive phase. Sleep-stage disruption, particularly of REM sleep, which is thought to restore cognitive performance [33,34], may be responsible for potentiating this deficit. Eszopiclone induced substantial changes in gamma and theta qEEG spectral power relative to vehicle for the entire resting period—a result consistent with both suppressed REM sleep and disrupted sleep-stage-specific EEG spectral activity observed in previous studies [15,20].

Conversely, the lack of qEEG spectral disruption by DORA-22 during the previous resting phase was associated with no such cognitive impairment. Currently, it is unclear whether the lack of cognitive impairment by DORA-22 is due to the promotion of unperturbed sleep or a lack of on-drug cognitive effects. Indeed, cognitive assessment of rhesus monkeys performed within 2 h following treatment indicated no impairment in DMS and SCRT tasks with DORA-22, but substantial deficits were induced by diazepam, eszopiclone, and zolpidem at sleep-promoting doses [24].

Even if DORA levels sufficient to exceed the OX$_2$R efficacy threshold are present at the onset of wake, emerging preclinical data indicate that these effects are expected to be benign relative to those induced by GABA-A receptor modulators. When evaluated acutely (< 4 h after treatment), DORAs have little or no impact on locomotor coordination in rats [35], or on memory or attention in rats and rhesus monkeys [24]. This is in
stark contrast to BzRMs or non-BzRMs, which induce substantial deficits when measured acutely [24,35]. While these differential effects remain to be investigated clinically, results in preclinical species indicate another fundamental difference between blockade of orexin signaling and GABA-A receptor activation.

The sleep promoting effect of DORAs is the result of the inhibition of orexin-induced arousal primarily mediated through OX2R. Genetically, loss of this receptor is associated with narcolepsy in dogs [36] and the hypersomnolent phenotype of mice lacking OX2R is similar to that of those lacking both receptors or Hert gene encoding orexin ligands [37,38], while OX1R KOs reportedly display only a minor sleep fragmentation phenotype [39]. Pharmacologically, OX2R selective antagonists induce sleep promoting effects similar to that of DORAs, while OX1R selective antagonists administered alone exhibit only minor, if detectable effects on vigilance state [29,30]. It has been suggested that OX1R inhibitory activity of DORAs may counter the effect of OX2R inhibition by these compounds through a dopamine-mediated mechanism [29], but further evaluation using alternative OX1R and OX2R selective antagonists of different selectivity has questioned this conclusion [30].

Based on these preclinical evaluations of structurally divergent DORAs, suvorexant exhibits a pharmacokinetic profile predicted to be advantageous for the treatment of insomnia. Analysis of the time course of suvorexant plasma concentrations determined in an early Phase 1 clinical trial indicates that concentrations sufficient for efficacy in humans (0.33 μM for 65% OX2R occupancy based on normalization from the rat transgenic model) are restricted to normal sleep periods while efficacy is maintained for a range of doses. Given their high OX2R occupancy threshold for efficacy, DORAs require a plasma concentration sufficient to maintain occupancy in order to promote sleep throughout the rest period in humans. For suvorexant, this is achieved with a plasma concentration T1/2 exceeding 8 h. In early clinical trials, suvorexant exhibited an apparent terminal T1/2 of 9 to 13 h [40] – pharmacokinetic timing appropriate for sleep maintenance.

Although insomnia is a common disorder, its underlying mechanisms are still not fully understood. DORAs have been rationally designed specifically to promote sleep by blocking wakefulness and thus alleviate the symptoms of insomnia while minimizing potential off-target activity that occurs with widespread signaling via GABA-A receptor modulators. By using antagonist compounds like suvorexant to block the arousal-promoting effects of orexin signaling in the brain, the oscillation in endogenous orexin pathway activation (highest signaling during active periods and diminished signaling during normal sleep times) is modified to mimic more closely the expected physiological state in normal sleep and wakefulness.

Conclusion

The combination of desirable pharmacokinetic and receptor-binding properties as well as a high level of OX2R occupancy necessary to antagonize the wake promoting effects of the endogenous orexin ligand allows DORAs to alleviate insomnia symptoms during normal sleep periods while avoiding residual somnolence during subsequent waking periods. These data support the thesis that DORAs such as suvorexant may have pharmacological and kinetic-binding properties appropriate for the treatment of insomnia.

Methods

All animal studies were performed in accordance with The National Research Council’s Guide for the Care and Use of Laboratory Animals (http://www.nap.edu/catalog.php?record_id=12910) and were approved by the Merck Institutional Animal Care and Use Committee. All efforts were made to minimize animal use and suffering.

Detection of orexin-A in cerebrospinal fluid

CSF was collected via cisterna magna puncture similarly from male and female beagles and rhesus monkeys (Macaca mulatta) similarly. Propofol (i.v., 2–8 mg/kg, to effect) anesthetized dogs were maintained on isofluorane anesthesia via an endotracheal tube. Using aseptic technique, a 1.5 inch spinal needle with stylet is introduced through the skin and subcutaneous tissue and then through the atlanto-occipital membrane which connects the first vertebrae with the skull and overlies the cisterna magna. The stylet is then removed from the needle and cerebrospinal fluid is allowed to flow into a collection tube. CSF was collected from conscious male and female rhesus monkeys (Macaca mulatta) using methods described previously [41], and similar to those procedures employed in dog.

CSF was collected from Male Sprague–Dawley rats (Taconic Farms, Hudson, NY) under isofluorane anesthesia (5% with oxygen at 2 L/min in an induction hood, 2% thereafter) and on a circulating water warming blanket. Heads were shaved from the posterior portion to the dorsal thoracic area exposing region just above the cisterna magna, and placed on stereotaxic apparatus to position the head of the rat at a 70-80° bend. After identifying the area by palpation, a 25 g × 5/8” butterfly needle, with 12” of tubing (Terumo Surflo Winged Infusion Set, Terumo Corporation, Somerset, NJ) is slowly inserted into the cisterna magna of the rat. A small suction is applied from a syringe connected to the end of the winged infusion set until fluid is observed in the tubing. CSF was then collected by expulsion into a microfuge tube. CSF was similarly collected.
from male C57BL/6 mice (Taconic Farms, Hudson, NY) except that the procedure is a non-survival surgery in mice, and animals are rapidly euthanized following CSF recovery. For mice, a stereotoxic device is fashioned from the styrofoam 15 mL conical tube holder, and skin and muscle covering the head and neck area are removed to visualize the dura mater prior to CSF collection.

Concentrations of OX-A within CSF were quantified by immunoassay developed using the Meso Scale Discovery (MSD) electrochemiluminescence detection technology platform (Gaithersburg, MD, USA). Purified polyclonal immunoglobulin G (G-003-36, Phoenix Peptide, Burlingame, CA, USA), raised in rabbit against OX-A (amino acids 16–33) amide, was used as the capture antibody. Goat anti-human polyclonal antibody against orexin-A (N-18) (sc-26491, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used as the primary detection antibody. Sulfo-Tag-labeled anti-goat antibody, raised in donkey, was used as the secondary detection antibody and was provided by MSD (R32AG-5). Assay wash buffer (R61TX-1) was also sourced from MSD. Blocking buffer was generated by dissolving membrane blocking agent (RPN-2125, GE Healthcare, Buckinghamshire, UK) in MSD wash buffer (1.5 g per 50 mL). Antibody and orexin standards (reconstituted in antibody diluent) or samples (25 μL per well) were added to each well. The plates were sealed and incubated, shaking for 2 h at room temperature. Following incubation with standards and samples, plates were washed an additional three times with 200 μL per well of wash buffer. Next, 25 μL of primary antibody dilution (1 μg per mL) was added to each well and plates were sealed and incubated while shaking for 1 h at room temperature. After aspirating blocking buffer, orexin standards (reconstituted in antibody diluent) or samples (25 μL) were added to each well. The plates were sealed and incubated, shaking for 2 h at room temperature. Following incubation with standards and samples, plates were washed an additional three times with 200 μL per well of wash buffer. Next, 25 μL of primary antibody dilution (1 μg per mL) was added to each well and plates were sealed and incubated while shaking for 1 h at room temperature. Following an additional wash step, 25 μL of secondary antibody dilution (0.5 μg per mL) was added to each well and plates were sealed and incubated, shaking, for 1 h at room temperature. As a final step, 150 μL of read buffer was added to each well and plates were read on an MSD sector imager. All measurements were performed in triplicate.

**EEG**

The mean time spent in sleep stages was determined in radio-telemetry-implanted mice, rats, dogs, and rhesus monkeys as first described by Renger and colleagues [42] and subsequently by Winrow and colleagues [12,18] with minor modifications. For baseline studies, recordings were taken continuously from unperturbed mice, rats, dogs, and monkeys for 6, 6, 10, or 5 days, respectively, and the mean time spent in all sleep stages in 30-min intervals were averaged and plotted onto a single 24-h period (Figure 1). Almorexant is a DORA [43] that was previously in clinical development for the treatment of insomnia [10,44]. The clinical development program for almorexant was terminated in early 2011. For rat studies in which DORA-22, DORA-12, or almorexant were administered, a balanced 3-day cross-over design was employed in which all animals were treated alternately with vehicle (20% Vitamin E d-alpha tocopheryl polyethylene glycol 1000 succinate [TPGS], orally [per os, p.o.]) and compound for 3 consecutive days with a 5-day intervening washout period, animals being divided randomly into either vehicle- or compound-first groups. In all cases, mean time in active wake, quiet wake, SWS, and REM sleep was determined for each 30-min interval for 3 days of each condition and averaged onto a single 24-h period. Automated sleep-stage data collection and analysis were performed as described in detail previously [12]. Statistical differences in mean time spent in active wake, quiet wake, SWS, and REM sleep between vehicle- and compound-treated groups at 30-min time points were determined by a linear mixed-effects model applied t-test.

EEG responses to diazepam (10 mg/kg, p.o. in 0.5% methylcellulose); eszopiclone (10 mg/kg, p.o. in 20% Vitamin E TPGS) and DORA 22 (30 mg/kg, p.o. in 20% Vitamin E TPGS) were evaluated in rhesus monkeys implanted with subcutaneous telemetric devices (D70-EEE; Data Sciences International, Arden Hills MN) housed in a 12:12 light cycle with lights-off at 16:30 and lights-on at 04:30. Animals were fed on a calorie-controlled diet of laboratory chow supplemented with fruit and vegetables. Water was available ad libitum with the exception of those monkeys trained to perform cognitive tasks, for which access was restricted for up to 4 h prior to and during cognitive testing. Treatment occurred at 14:40 (Zeitgeber time [ZT] 10:10) in a balanced 1-day cross-over design: 1 day of drug or vehicle followed by 6 days of baseline followed by 1 day of vehicle or drug. Cognition tasks were scheduled for next-day evaluation as described below. Sleep/wake architecture was scored according to vigilance state (active wake, quiet wake, delta sleep I, delta sleep II, and REM sleep) at 30-minute intervals and analyzed as previously described [24]. Spectral analysis of continuous EEG was quantified between vehicle and compound after binning continuous frequencies into canonical frequency bands (reported herein: Delta, 0.5 – 4 Hz;
Theta, 4.0 – 7 Hz; Gamma, 35.0 – 100.0 Hz). qEEG values are spectral power (uV^2) log transformed before analysis and averaged over 30-minute intervals, expressed as means +/- SEM, and compared with vehicle using a mixed-model ANOVA at each time point with random effects for subject and date within subject in the R statistical computing environment (cran.us.r-project.org; the R Foundation for Statistical Computing, Vienna, Austria) using a linear mixed effects model for significance testing. Significant conditional differences are indicated as tick marks at the top of the graphs (short, \( P \leq 0.05 \); medium, \( P \leq 0.01 \); long, \( P \leq 0.001 \)) with gray vertical bars through significantly different data points.

**OX2R occupancy**

Occupancy of human OX2R in transgenic rats expressing the receptor via the rat enolase promoter was performed *ex vivo* in radioligand-binding-displacement assays essentially as previously described [21] with minor modifications. To determine the relationship between OX2R occupancy for a given compound over a full range of plasma and CSF concentrations, hOX2R-expressing rats were dosed i.v. with compound. Immediately following 30 min of i.v. administration, animals were anesthetized, sacrificed, and CSF, blood, and brain tissue were harvested and frozen for analysis. Frozen tissue was weighed and thawed coincident with homogenization. The homogenate was pelleted at 21,000 × g for 1 min and the pellet was resuspended. A binding assay was run with brain tissue and radio ligand at ~ 10 × K_d and filtered at 12 min (in the linear association phase). Non-specific binding was determined by the addition of 1000-fold excess unlabeled ligand. Experimental (dosed)-specific binding was compared with control (vehicle-dosed) binding ([specific total counts minus specific experimental counts]/specific total counts × 100 = percent occupancy). Raw occupancy values determined in this manner over a range of plasma and CSF values were then used to construct a normalized curve where the theoretical maximum occupancy value was defined as 100% and occupancies relative to plasma or CSF values were fit to a one-sided binding (hyperbola) curve (GraphPad Prism, San Diego, CA, USA). Plasma values determined from PSG experiments in satellite animals were then used to determine corresponding occupancy values from best fit curves for a given compound at C_{max}. In separate experiments, plasma, CSF, and brain tissue was collected at time points following dosing to directly measure compound levels and corresponding OX2R occupancies at these times. Resulting occupancy relative to measured plasma levels of compound was fit to a normalized binding curve as described previously [21].

OX2R occupancy in dogs and humans was calculated based on the plasma/occupancy relation determined in rats and corrected for the free fraction of suvorexant in each species. In dogs, suvorexant plasma levels determined in satellite animals coincident with PSG studies reported by Winrow and colleagues [12] were used to calculate OX2R occupancy levels based on standard curves of OX2R occupancy in rats versus the free fraction of plasma suvorexant levels. Human free plasma levels of suvorexant sufficient for 80% OX2R occupancy were calculated based on extensive rat data and normalized for free fraction (rat: 1.4%; human: 1%). The plasma level of suvorexant calculated to correspond to 80% OX2R occupancy in humans is 0.71 μM (free + bound) [17]. Human plasma levels of suvorexant collected in Phase 1 (10, 20, 50, and 76 mg doses) and Phase 2/3 (steady state, 40 mg) clinical trials were plotted against the suvorexant plasma value calculated to correspond to the exposure required for the OX2R occupancy determined from standard OX2R occupancy versus free fraction exposure curves of preclinical species.

**Monkey Delayed Match to Sample (DMS) task**

All cognition testing occurred in the animal’s home cage equipped with a touchscreen. Each DMS trial was initiated with a single ‘sample’ image (150 × 200 pixels: 1.8 inches × 2.3 inches) in one of eight colors presented at the center of a touchscreen. Evaluation began when the monkey touched the sample image, at which point the screen became blank for a retention period. Following the retention period, four choice images (150 × 200 pixels) were presented, one in each corner of the screen. One of the four choice images matched the color of the sample image, whereas the three remaining ‘distractor’ images were drawn from the pool of remaining colors. A reinforcer was provided when the monkey touched the choice image that matched the color of the sample image. Incorrect choices were not reinforced and resulted in a 5 s timeout. On completion of the trial, an inter-trial interval of 5 s was presented prior to the next trial, and failure to respond to the samples or choice images within 30 s resulted in the screen turning blank for a 5 s timeout prior to initiating another trial. Test sessions comprised 96 trials or lasted for up to 45 min. Three discrete retention intervals were titrated for each subject’s baseline performance in the absence of compound to yield performances of approximately 80–100%, 55–65%, and 35–45% of responses being correct at short, medium, and long retention intervals, and ranged from 0.25–0.5 s, 2.5–14 s, and 9–39 s, respectively. Response latencies to sample and choice images were also recorded. Values reported reflect the proportion of correct responses collapsed over all retention intervals.
Differences from vehicle were examined using repeated measures ANOVA.

**Monkey Serial Choice Reaction Time (SCRT) task**

Each SCRT trial was initiated with the appearance of 10 blue square ‘target’ images evenly distributed at 3-inch intervals around the perimeter of a touchscreen presented together with a centrally located circular ‘centering’ image (1.4 inch diameter circle). The task began with the monkey touching the centering image, which then turned gray. The monkey was then required to touch the centering image continuously throughout a variable pre-cue interval of 0.25–7.5 s. On completion of the pre-cue interval, one of the blue target images was cued by turning red for one of four cue durations before turning back to blue. To obtain a reward, the monkey was required to touch the target image that had been ‘cued’ red within a 5 s limited hold period. Inaccurate choices were not reinforced and resulted in a 3 s timeout. On completion of the trial, an inter-trial interval of 2 s was initiated prior to the next trial. A failure to respond to the centering image within 60 s resulted in the screen becoming blank for a 2 s timeout prior to the start of the next trial. If the monkey initiated a trial but removed its hand from the touchscreen prior to the appearance of the cue, the trial was terminated and the screen was blanked during a 2 s inter-trial interval. Sessions were terminated after 20 min. Cue location and duration were pseudo-randomly assigned. Cue duration and the target size were titrated for each subject on the basis of performance during previous baseline sessions to yield a performance of 60–80% correct responses for the trials of the shortest cue duration. The briefest cue duration varied from 0.04–0.1 s and the cues varied in size from 0.2–0.7 inches, although each cue had the same touch-sensitive area of 1.75 inches. Values reported in the current study reflect the proportion of correct responses to targets after cue durations of the shortest duration only.

**Authors’ contributions**

ALG, CWM, JWR wrote and edited major portions of the manuscript with significant interpretive and editorial comments by all authors, particularly SDK, PJ, TMCD, and PLT Rodein, dog and rhesus orexin level determinations were performed by JB with analytical and technical contributed by LY SLG, JB, JS, AS and SVF performed rodent polysomnography studies with study design, additional data analysis and interpretation contributed by ALG, PLT, and JIR Monkey polysomnography studies were performed by JB, AS, and SJT with study design, additional data analysis and interpretation contributed by ALG, PLT, and JIR Monkey cognition study design, analysis and interpretation by SJT, JU and AS Pharmacokinetic analysis and interpretation by DC, KLY, SDK and ALG Occupancy study execution and analysis by MS, CMH with study design, additional analysis and interpretation by ALG, DC, KLY All authors’ read and approved the final manuscript.

**Acknowledgements**

All authors are employed by Merck Research Laboratories, receive salary and research support from Merck and Co., Inc., and potentially own stock in the company. Editorial support was provided by Gary Dever, Ph.D. at Complete Medical Communications and was funded by Merck & Co., Inc.

**References**

1. España RA, Scammell TE: Sleep neurobiology from a clinical perspective. Sleep 2011, 34:845–858.
2. Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ: International Union of Basic and Clinical Pharmacology: LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol Rev 2012, 64:389–420.
3. Taheri S, Duner D, Dabin C, Moyes S, Seal L, Gardiner J, Rossi M, Ghatie M, Bloom S: Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system. Neurosci Lett 2000, 279:109–112.
4. Zeitler JM, Buckmaster CL, Parker KJ, Hauch CM, Lyons DM, Migone T: Circadian and homeostatic regulation of hypocretin in a primate model: Implications for the consolidation of wakefulness. J Neurosci 2003, 23:3555–3560.
5. De Lecea L, Kilduff TS, Peyron C, Gao XB, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG: The hypocretins: Hypothalamic-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322–327.
6. Sakurai T, Amemiya A, Ishitii M, Matsuelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RE, Haynes AC, Can SA, Annan RS, McInulty DE, Liu WS, Terrett JA, Elthorhubaghy NA, Bergsma DJ, Yanagisawa M: Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573–585.
7. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmede TE, Shah AS, Hatcher JF, Hatcher JD, Jones DBC, Smith MJ, Piper DC, Hunter AJ, Porter NI: Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999, 96:10911–10916.
8. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649–4654.
9. Piper DC, Upton N, Smith MJ, Hunter AJ: The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000, 12:726–730.
10. Brisbane-Roch C, Dangemans J, Koberstein R, Hoever R, Aissouaou H, Flores S, Muiller C, Nayer O, Van Gerven J, De Haas SL, Hess P, Qiu CB, Buchmann S, Schez M, Weller T, Fischl W, Clozel M, Jenck F: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007, 13:150–155.
11. Li AH, Nartse E: Antagonism of rat orexin receptors by almorexant attenuates central chemoception in wakefulness in the active period of the diurnal cycle. J Physiol 2010, 588:B2935–2944.
12. Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Gannon SL, Fox SV, Hanell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ: Promotion of sleep by suvorexant - a novel dual orexin receptor antagonist. J Neurogenet 2011, 25:52–61.
13. Roehrs T, Roth T: Insomnia pharmacotherapy. Neurotherapeutics 2012, 9:728–738.
14. Roth T: A physiologic basis for the evolution of pharmacotherapy for insomnia. J Clin Psychiatry 2007, 68(Suppl 3):13–18.
15. Berretta P, Squassiani L, Groeger JA, Gennery B, Winko-Sommerer R, Drijf DJ: Differential effects of a dual orexin receptor antagonist (SB-649860) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012, 37:1224–1233.
16. Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gennard P, Porter RA, Johnson CN, Thewlis K, Donati D, Stasi L, Spada S, Stemp G, Nash D, Branch...
C. Kindon, L. Massagrande, M. Poffe, A. Braggio, S. Chiariapin, E. Marchioro, C. Ratti, E. Corsi: Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett 2011, 21:5562–5567.

17. Herring WJ, Snyder E, Budd K, Hetzelmann J, Snively D, Liu K, Lines C, Roth T, Michelsohn D: Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant. Neurology 2012, 79:2265–2274.

18. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger J: Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology 2012, 62:978–987.

19. Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Boguski MJ, McGaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, Cabalu TD, Cui D, Prieur-antonnant T, Stevens J, Tannenbaum PL, Ball RG, Stellabot J, Young SD, Hartman GD, Winrow CJ, Renger J: Discovery of [(2S)-[(5S)-[5-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)methyl]-2-(methylpiperidin-1-yl)]-methyl]-2-(3,5-dimethylphenyl)propan-2-amine (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012, 7:415–24. 337.

20. Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JJ, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger J: Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropharmacology 2013. doi:10.1016/j.nphar.2013.139.

21. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Boguski MJ, Roeker AJ, Mercer SP, Bednar RA, Lemaire W, Bravo JS, Reiss DR, Harrell CM, Murphy ML, Garson SL, Doran SM, Prieur-antonnant T, Anderson WB, Tang C, Poller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger J, Coleman PJ: Discovery of the dual orexin receptor antagonist [(7R)-1-(4-fluoro-1H-chloro-2-benzoxazol-6-yl)-methyl]-1-(3,5-dimethyl-4-phenyl)piperidine hydrochloride ((MK-6305); a dual orexin receptor antagonist, in healthy male subjects. J Med Chem 2010, 53:5320–5332.

22. Gotter AL, Roeker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger J: Orexin receptors as therapeutic drug targets. Prog Brain Res 2012, 198:153–88.

23. Faedo S, Perdona E, Antolin M, DI FR, Merlo PE, Corsi M: Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists. Eur J Pharmacol 2012, 692:1–9.

24. Uslaner JM, Tyje SI, Daddins DM, Wang X, Fox SV, Savitz AT, Bins J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowby MR, Tannenbaum PL, Brunner J, McDonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger J: Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013, 5:179ra44.

25. Abadie P, Roux P, Scatton B, Zarifian E, Barre L, Patat A, Baron JC: Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. Eur J Pharmacol 1996, 295:35–44.

26. Martins PJ, D’Almeida V, Pedrazzoli M, Lin L, Mignot E, Tufik S: Increased hypocretin-1 (orexin-a) levels in cerebrospinal fluid of rats after short-term forced activity. Regul Pept 2004, 117:155–8.

27. Allen RP, Mignot E, Ripley B, Nishino S, Earley CJ: Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 2002, 59:539–41.

28. Nishino S, Ripley B, Oeverem S, Lammers GM, Mignot E: Orexin (hypocretin) deficiency in human narcolepsy. Lancet 2000, 355:59–40.

29. Dugovic C, Shilton JE, Alusio LE, Fraser IC, Jang XH, Sutton SW, Bonaventure P, Yun S, Li XR, Lord D, Dvorak CA, Carruthers NL, Lovenberg TW: Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat. J Pharmacol Exp Ther 2009, 330:142–151.

30. Mosarity SR, Revel FG, Malherbe P, Moreau JL, Valladalo D, Wettgen JS, Kilduff TS, Borroni E: Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 2012, 7:e39131.

31. Farde L, Nordström AI, Wiesel FA, Pauli S, Hallidin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992, 49:538–44.

32. Wong DF, Taucher J, Grünner G: The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009, 34:187–203.

33. Dijk DJ, James LM, Peters S, Walsh JK, Deacon S: Sex differences and the effect of gaboxadol and zolpidem on EEG power spectra in NREM and REM sleep. J Psychophysiol 2010, 24:163–168.

34. Walsh JK, Deacon S, Dijk DJ, Lundahl J: The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep 2007, 30:593–602.

35. Steiner MA, Lecourt H, Strasser DS, Brisbane-Roch C, Jenck F: Differential effects of the dual orexin receptor antagonist almorexant and the GABA (A)-alpha1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 2011, 36:848–856.

36. Lin J, Faraco J, Li R, Kadotani H, Rogren W, Lin YX, Qiu XH, De Jong PJ, Nishino S, Mignot E: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365–376.

37. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell TE, Lee C, Richardson JA, Williams SC, Xiong YM, Kisanyuk Y, Fitch TE, Nakamoto M, Hammer RE, Saper CB, Yanagisawa M: Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999, 98:437–451.

38. Chemelli RM, Chemelli RM, Sinton CM, Tokita H, Williams SC, Kisanyuk YY, Marcus IN, Lee C, Elmquist JK, Kohlaneier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M: Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715–730.

39. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M: To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001, 24:429–458.

40. Sun H, Kennedy D, Lewis N, Laethem T, Yee K, Li X, Hoon J, Van Bortel L, Rosen L, Chodakewitz J, Wagner JA, Murphy MG: The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305): a dual orexin receptor antagonist, in healthy male subjects. Clin Pharmacol Ther 2012, 91(Suppl 1):S29.

41. Gilberto DB, Zeoli AH, Szczerba PJ, Gehret JR, Holahan MA, Sitko GR, Johnson CA, Cock JJ, Motzelt SL: An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp Top Lab Anim Sci 2003, 42:53–59.

42. Renger J, Dunn SL, Motzelt SL, Johnson C, Koblan KS: Sub-chronic administration of zolpidem affects modifications to rat sleep architecture. Brain Res 2004, 1010:45–54.

43. Malherbe P, Borroni E, Pinard E, Wettstein JK, Kroflach F: Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol 2009, 76:618–631.

44. Dingemans J, Dorthor G, Hajak G, Benes H, Danker-Hopfe H, Polo O, Saletu B, Barbanoj MJ, Pillar G, Perez T, Chissi E, Hoefer P: Proof-of-concept study in primary insomnia patients with ACT-078373, a dual orexin receptor antagonist [abstract]. Sleep Biol Rhythms (5th World Congr World Fed Resp Res Sleep Med Soc) 2007, 5(Suppl):A194.